OxyContin Ads Will Highlight Boxed Warning In Response To FDA Objection
Executive Summary
Purdue is revising its OxyContin ads to prominently feature black box warnings found in labeling following receipt of a warning letter from FDA
You may also be interested in...
Purdue Execs Plead Guilty To Misbranding OxyContin; Company Pays $700 Mil.
While other companies have been hit with heftier fines for falsely marketing their drugs, Purdue Pharma's $700.6 million agreement with the Department of Justice over OxyContin promotions has had a profound impact on the management of the company, with guilty pleas from two of the firm's top executives
Purdue Execs Plead Guilty To Misbranding OxyContin; Company Pays $700 Mil.
While other companies have been hit with heftier fines for falsely marketing their drugs, Purdue Pharma's $700.6 million agreement with the Department of Justice over OxyContin promotions has had a profound impact on the management of the company, with guilty pleas from two of the firm's top executives
FDA Preclearance Of DTC Ads Included In Sen. Kennedy Draft Bill
Repeat offenders of direct-to-consumer advertising regulations would be required to submit all future ads to FDA for preclearance under a draft bill sponsored by Sen. Edward Kennedy (D-Mass.)